MetLife (MET) reported $17.92 billion in revenue for the quarter ended June 2025, representing a year-over-year decline of 4.1%. EPS of $2.02 for the same period compares to $2.28 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $18.39 billion, representing a surprise of -2.58%. The company delivered an EPS surprise of -7.76%, with the consensus EPS estimate being $2.19.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how MetLife performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:- Adjusted Revenue- EMEA- Universal life and investment-type product policy fees: $84 million compared to the $79.75 million average estimate based on three analysts. The reported number represents a change of +9.1% year over year.
- Adjusted Revenue- Corporate & other- Premiums: $8 million compared to the $8.73 million average estimate based on three analysts. The reported number represents a change of -46.7% year over year.
- Adjusted Revenue- EMEA- Other Revenues: $9 million versus $8.44 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +12.5% change.
- Adjusted Revenue- Corporate & other- Other Revenues: $118 million versus $100.33 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +21.7% change.
- Revenue- Premiums: $10.81 billion versus the five-analyst average estimate of $11.29 billion. The reported number represents a year-over-year change of -7%.
- Revenue- Other Revenues: $679 million versus $656.89 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +6.4% change.
- Revenue- Universal life and investment-type product policy fees: $1.26 billion versus the five-analyst average estimate of $1.28 billion. The reported number represents a year-over-year change of -1.7%.
- Revenue- Net investment income: $5.66 billion versus $5.13 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +8.8% change.
- Adjusted Revenue- Retirement & Income Solutions- Premiums: $1.21 billion compared to the $1.79 billion average estimate based on three analysts. The reported number represents a change of -50.6% year over year.
- Adjusted Revenue- Retirement & Income Solutions- Universal life and investment-type product policy fees: $85 million compared to the $90.7 million average estimate based on three analysts. The reported number represents a change of +16.4% year over year.
- Adjusted Revenue- Retirement & Income Solutions- Net investment income: $2.15 billion compared to the $2.15 billion average estimate based on three analysts. The reported number represents a change of +1.3% year over year.
- Adjusted Revenue- Retirement & Income Solutions- Other Revenues: $60 million versus $59.67 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -1.6% change.
View all Key Company Metrics for MetLife here>>>
Shares of MetLife have returned -6% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Zacks' Research Chief Picks Stock Most Likely to "At Least Double"
Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.
See Our Top Stock to Double (Plus 4 Runners Up) >>MetLife, Inc. (MET) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
